N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Early Phase 1 N=15 Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Vascular Stiffness · Insulin Sensitivity
Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
N/A N=8 Acute Microvascular Changes With LDL Apheresis
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
N/A N=35 Hyperglycemia and Mitochondrial Function in The Endothelium of Humans
Diabetes · Hyperglycemia
Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)
N/A N=47 Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training — -24; -20; -23; -21 percentage of…
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
N/A N=142 Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Shock · Cardiovascular Diseases · Critical Illness
Primary: Perfused Vessel Denisty (PVD) — 22.8; 23.8; 20.2; 22.5 mm/mm^2
Early Phase 1 N=23 Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
N/A N=30 Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction
Primary: Change in Coronary Flow Reserve (CFR) — 3.04 ratio — p=0.0137
N/A N=41 Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
N/A N=80 Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial Infarction · No-Reflow Phenomenon
Primary: Hospital Mortality Rate — 6; 2 Participants
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
N/A N=23 Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Prediabetes
Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min
N/A N=99 Effects of Walking and Heating on Vascular Function in Diabetic Patients
Type 2 Diabetes Mellitus · Obesity
Primary: Insulin-stimulated Leg Blood Flow Calculated as Percent Change (t0, t60) — 133.6; 8.92 percentage change
N/A N=70 Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea
Obstructive Sleep Apnea · Hypoxemia
Primary: ODI — 24.71; .97 events/hour
Early Phase 1 N=26 Sex Differences in the Dilatory Response of Compound 21
Sex Differences
Primary: Microvascular AT2R Sensitivity Following Local Control Treatment — 15; 25 percentage of maximal blood flow
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 4 N=44 Lovaza® and Microvascular Function in Type 2 Diabetes
Hypertriglyceridemia · Diabetic Neuropathy
Primary: Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude. — 7.28; 7.14; 4.08; 3.80 uV
Phase 2 N=26 CD36 in Nutrient Delivery and Its Dysfunction
Insulin Resistance · Endothelial Dysfunction
Primary: Change in Microvascular Blood Volume (MBV) During Insulin Infusion — 13.16; 11.3 ml/kg
N/A N=30 Role of Flavanols In Cardiovascular Function in Healthy Aging
Aging
Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow
N/A N=11 Cerebrovascular Dysregulation in Chronic Kidney Disease
Chronic Kidney Diseases
Primary: Mean Arterial Pressure-Middle Cerebral Artery Blood Velocity Very Low Frequency Phase (Radians) — 1.38; 1.12; 1.40; 1.60 Radians — p=0.05